Although RAC1 inhibitor drugs are not currently available in clinical practice, SRF/MRTF inhibitors in combination with BRAF inhibitors have recently been shown to be effective in the treatment of BRAF mutant melanoma cells with a co-occurring RAC1 P29S mutation [43]. This evidence concerns the gene SRF and melanoma.